Researchers at Baylor College of Medicine have discovered a natural mechanism that clears existing amyloid plaques in the ...

Alzheimer's disease (AD), a progressive neurodegenerative disorder, is one of the leading causes of dementia worldwide, and ...

A new study shows that oral arginine, a naturally occurring amino acid, can significantly suppress amyloid-β aggregation in Alzheimer’s disease models.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer ...

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

Rice University Nov. 18 launched the Amyloid Mechanism and Disease Center, a new campus hub dedicated to uncovering the ...

A team of researchers at the Federal University of ABC (UFABC) in Brazil has developed a new chemical compound with the ...

Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology ...

A new blood test for Alzheimer’s disease may feel like a breakthrough for anyone seeking to understand the cause of their ...

A method for detecting early signs of Alzheimer's disease using amyloid PET imaging works as well as the previously used cerebrospinal fluid sample method. This is the conclusion of a new Lund ...

The idea that sticky brain plaques cause Alzheimer’s disease began as an interesting hypothesis and eventually became drug industry dogma. Now, after a string of clinical trial failures, that ...

Alzheimer's disease (AD) is thought to affect ∼10% of people over the age of 65 and ∼50% of people over 85. It is not the only disease that involves the abnormal deposition of proteins into structures ...